

## The Macmillan HORIZONS Programme

Chief Investigator: Professor Claire Foster, Macmillan Survivorship Research Group, Health Sciences, University of Southampton

Chair of the HORIZONS NHL Tumour Specific Expert Panel: Professor Andy Davies, University Hospitals Southampton

Correspondence to: Dr Lynn Calman [L.Calman@soton.ac.uk], Macmillan Survivorship Research Group, Health Sciences, University of Southampton

### HORIZONS study design

A UK wide prospective cohort study exploring recovery of health and well-being of adults diagnosed with cancer and treated with curative intent.

#### Map of sites




#### Recruitment

- 110 NHS treatment centres across the UK recruited between September 2016 and March 2019.
- Newly diagnosed patients due to have curative intent treatment were invited to participate; sites provided aggregate data on decliners.
- Pre-treatment (baseline) clinical and self-reported information was collected from the sites and full consenters.
- Planned follow-up: up to 5 years.

### Recruitment & participation at baseline

A total of 3,334 eligible participants consented to take part in HORIZONS across the three cohorts. Of these, 719 were in the NHL cohort, as shown in the flow diagram below.



### HORIZONS cohorts

- ❖ **Non-Hodgkin lymphoma:** patients with Diffuse Large B Cell lymphoma
- ❖ **Breast cancer:** women diagnosed at age 50 or younger
- ❖ **Gynaecological cancers:** women with cervical, endometrial, ovarian or vulval cancer

Full information on sample inclusion/exclusion criteria, conceptual framework and data collected in the Macmillan HORIZONS programme can be found in the published protocol Foster *et al* (2019) BMJ Open.

### Measures

**Questionnaires:** socio-demographics, validated Patient Reported Outcome Measures (PROMs) and open-ended questions – self-reported by participants



**Case Report Forms (CRFs):** Clinical information from medical records on diagnosis, treatment, recurrence, co-morbidities, etc. - collected from sites



### Descriptive results (NHL cohort) at baseline

Socio-demographic characteristics (Questionnaire-based)	N (%)
Mean age at diagnosis [range]	66 [23-94]
Male	329 (57%)
White British	522 (90%)
Married/cohabiting	416 (72%)
Living alone	108 (19%)
Caring for children <18 years	57 (10%)
Living in owner occupied accommodation	459 (79%)
Above compulsory education	394 (68%)
In full-time employment	107 (18%)

Clinical and health characteristics (CRF-based)	N (%)
Stage 1 or 2	260 (38%)
Stage 3 or 4	292 (42%)
Letter Stage B	231 (33%)
Bulky disease	132 (19%)
ECOG 0 or 1	606 (87%)
Any comorbidity	447 (64%)

### Collaborate and use the data

We encourage collaboration and facilitate data sharing by researchers from all disciplines. Our Data Access Policy and application forms are available at: [www.horizons-hub.org.uk/access\\_data.html](http://www.horizons-hub.org.uk/access_data.html)

#### Acknowledgements

The Macmillan HORIZONS programme is funded by Macmillan Cancer Support. We would like to thank all HORIZONS participants, staff at our study sites, our HORIZONS Strategic Advisory Board, Programme Management Group, Tumour Specific Expert Panels, User Reference Group, and members of the Macmillan Survivorship Research Group.

#### Reference

Foster C, Calman L, Richardson A, et al (2019) HORIZONS protocol: a UK prospective cohort study to explore recovery of health and well-being in adults diagnosed with cancer. BMJ Open, 9:e029662.